...
首页> 外文期刊>Veterinary Parasitology >Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro
【24h】

Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro

机译:伊维菌素与酪氨酸激酶/ P-糖蛋白抑制剂克唑替尼在体外对捻转血矛线虫幼虫的协同作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Anthelmintic resistance is a major problem in parasitic nematodes of livestock worldwide. One means to counter resistance is to use synergists that specifically inhibit resistance mechanisms in order to restore the toxicity, and hence preserve the usefulness, of currently available anthelmintics. P-glycoproteins (P-gps) eliminate a wide variety of structurally unrelated xenobiotics from cells, and have been implicated in anthelmintic resistance. Crizotinib is a tyrosine kinase inhibitor under development as a cancer therapeutic. The compound also inhibits P-gps, and has been shown to reverse multidrug resistance in cancer cells. We were therefore interested in determining if the compound was able to increase the sensitivity of Haemonchus contortus larvae to ivermectin, as measured by in vitro larval development and migration assays with a drug-resistant and a-susceptible isolate. In migration assays, co-administration of crizotinib increased the toxicity of ivermectin to resistant larvae (up to 5.7-fold decrease in ivermectin IC50), and rendered the resistant larvae equally or more sensitive to ivermectin than the susceptible isolate. On the other hand, co-administration of crizotinib had no effect on ivermectin sensitivity in the susceptible isolate. In development assays, significant increases in the sensitivity of both the resistant (up to 1.9 fold) and susceptible (up to 1.6-fold) larvae to ivermectin were observed, although the magnitude of the observed synergism was less than seen in migration assays, and the resistant larvae retained significant levels of ivermectin resistance. By highlighting the ability of the P-gp inhibitor crizotinib to increase the sensitivity of H. contortus larvae to ivermectin, this study provides further evidence that P-gp inhibitors are potential tools for modulating the efficacy of anthelmintics. In addition, the differences in the outcomes of the two assays, with 'resistance-breaking' effects being much more marked in migration assays, suggest that some life-stage-specific aspects may exist in the interaction of ivermectin with P-gps in the two worm isolates. (C) 2016 Elsevier B.V. All rights reserved.
机译:驱虫抗性是全世界牲畜的寄生线虫的主要问题。对抗耐药性的一种方法是使用能特异性抑制耐药性机制的增效剂,以恢复目前可用的驱虫药的毒性,从而保持其实用性。 P-糖蛋白(P-gps)从细胞中消除了多种结构上不相关的异生物素,并与驱虫药耐药性有关。克唑替尼是一种正在开发中的酪氨酸激酶抑制剂,可用于治疗癌症。该化合物还抑制P-gps,并已显示出可逆转癌细胞中的多药耐药性。因此,我们感兴趣的是确定该化合物是否能够增加捻转Haemonchus contortus幼虫对伊维菌素的敏感性,这是通过体外幼虫发育和迁移试验以及耐药性和α-敏感性分离物测定的。在迁移试验中,克唑替尼的共同给药增加了伊维菌素对耐药性幼虫的毒性(伊维菌素IC50降低多达5.7倍),并使耐药性幼虫对伊维菌素的敏感性比敏感菌株更高。另一方面,克唑替尼的共同给药对易感分离物中的伊维菌素敏感性没有影响。在发育试验中,虽然观察到的协同作用的强度小于迁移试验中观察到的协同作用的幅度,但观察到的抗性幼虫(最高达1.9倍)和易感幼虫(最高达1.6倍)对伊维菌素的敏感性均显着提高。抗性幼虫保留了显着水平的伊维菌素抗性。通过强调P-gp抑制剂crizotinib增加锥状嗜血杆菌幼虫对伊维菌素的敏感性的能力,本研究提供了进一步的证据,表明P-gp抑制剂是调节驱虫药功效的潜在工具。此外,两种测定结果的差异(在迁移测定中“抗性破坏”效应更为明显)表明,伊维菌素与P-gps相互作用可能存在某些生命阶段特异性方面。两个蠕虫分离株。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号